Cost effectiveness of recombinant factor VIIa for treatment of intracerebral hemorrhage
<p>Abstract</p> <p>Background</p> <p>Phase I/II placebo-controlled clinical trials of recombinant Factor VIIa (rFVIIa) suggested that administration of rFVIIa within 4 hours after onset of intracerebral hemorrhage (ICH) is safe, limits ICH growth, and improves outcomes....
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2008-05-01
|
| Series: | BMC Neurology |
| Online Access: | http://www.biomedcentral.com/1471-2377/8/17 |